| 2024-09-16 |
Alligator Bioscience AB |
Results Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study alligatorbioscience.se ↗
|
| 2024-03-07 |
Alligator Bioscience AB |
Results Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 alligatorbioscience.se ↗
|
| 2022-11-09 |
Alligator Bioscience AB |
Results Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics alligatorbioscience.se ↗
ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB Antibody |
| 2021-11-12 |
Alligator Bioscience AB |
Results Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021 alligatorbioscience.se ↗
The poster highlights preclinical datasets as an overview of the potential indication landscape, mechanism of action and the efficacy profile of ALG.APV-527, which support the molecule’s progression into the clinic. |
| 2020-06-10 |
Alligator Bioscience AB |
Results Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit alligatorbioscience.se ↗
|
| 2019-11-08 |
Alligator Bioscience AB |
Results Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting alligatorbioscience.se ↗
The preclinical data presented at SITC show that ALG.APV-527 selectively enhances T cell and NK cell responses in the presence of 5T4 in vitro and displays potent and sustained tumor suppression in vivo. |
| 2018-11-09 |
Alligator Bioscience AB |
Results Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting alligatorbioscience.se ↗
The preclinical data show that ALG.APV-527 localizes to 5T4 positive tumors and selectively stimulates and enhances tumor-directed T cell and NK cell responses, displaying potent anti-tumor effects. |
| 2018-05-08 |
Alligator Bioscience AB |
Results New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics alligatorbioscience.se ↗
New ALG.APV-527 preclinical data show that ALG.APV-527 has the potential to selectively activate and enhance tumor specific T cell responses at the tumor site without triggering systemic immune activation. |